Back to Rankings

NVO

Novo Nordisk A/SC
NYSE / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-21
View Chart
+
Peers tracked
10
U.S. public peers
Grade Position
In line
vs peer average
NVO vs peer average
55/100
NVO vs. peer average (C vs. C)
Grade spread
B 2 · C 4 · D 3 · F 1
Graded peers loaded
Coverage
10 graded
100% of tracked

Peer overview

LLY is the first available peer comparator.

Closest commercial obesity and diabetes competitor; the cleanest read-through on U.S. pricing, access, and category share for Novo's Wegovy franchise.

Peer source comes from the stored AI memo or peer model
Grades and factor rows use RankAlpha API data when available
Missing peer scores remain blank instead of being estimated
Side-by-side comparison keeps the data contract visible
Top peerLLYEli Lilly and
NVO
Novo Nordisk A/S
LLY
Eli Lilly and
Grade
C
C
Momentum
54
48
Value
57
59
Sentiment
46
54
Setup Bias
Net —
-
Market Cap
-
-
Posture
Mixed
Mixed

Grade position vs LLY

NVO / LLY
Grade Position
In line
NVO vs. peer average (C vs. C)
55/100
Momentum
54
NVO
Value
57
LLY
Sentiment
46
LLY

Rotation landscape

Peers ranked by the order returned from the peer source, with grades from the API.

Rank
Ticker
Company
Grade
Grade score
vs NVO
1
LLY
LLY
C
60/100
Even
2
AMGN
AMGN
D
40/100
+1
3
VKTX
VKTX
B
80/100
-1
4
TMO
Thermo Fisher Scientific Inc Common
B
80/100
-1
5
AZN
AstraZeneca PLC Common
F
20/100
+2
LLY is the first peer returned for this comparison set.